Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The REP 201 protocol is a small exploratory study assessing the antiviral effects and
tolerability of REP 2139-Ca when used with a full course of pegylated interferon (48 weeks)
in treatment naive patients or in patients already receiving entecavir and continuing
entecavir with treatment.